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Abstract
Background: Conjugated linoleic acid (cis-9, trans-11 CLA) and trans-11 vaccenic acid (VA) are found naturally in
ruminant-derived foods. CLA has been shown to have numerous potential health related effects and has been
extensively investigated. More recently, we have shown that VA has lipid-lowering properties associated with
reduced hepatic lipidogenesis and chylomicron secretion in the JCR:LA-cp rat. The aim of this study was to
evaluate potential additional hypolipidemic effects of purified forms of CLA and VA in an animal model of the
metabolic syndrome (the JCR:LA-cp rat).
Methods: Twenty four obese JCR:LA-cp rats were randomized and assigned to one of three nutritionally adequate
iso-caloric diets containing 1% w/w cholesterol and 15% w/w fat for 16 wk: 1) control diet (CD), 2) 1.0% w/w cis-9,
trans-11 CLA (CLA), 3) 1.0% w/w VA and 1% w/w cis-9, trans-11 CLA (VA+CLA). Lean rats were fed the CD to
represent normolipidemic conditions.
Results: Fasting plasma triglyceride (TG), total cholesterol and LDL-cholesterol concentrations were reduced in
obese rats fed either the CLA diet or the VA+CLA diet as compared to the obese control group (p < 0.05, p <
0.001; p < 0.001, p < 0.01; p < 0.01, p < 0.001, respectively). The VA+CLA diet reduced plasma TG and LDL-
cholesterol to the level of the normolipidemic lean rats and further decreased nonesterified fatty acids compared
to the CLA diet alone. Interestingly, rats fed the VA+CLA diet had a higher food intake but lower body weight
than the CLA fed group (P < 0.05). Liver weight and TG content were lower in rats fed either CLA (p < 0.05) or VA
+CLA diets (p < 0.001) compared to obese control, consistent with a decreased relative protein abundance of
hepatic acetyl-CoA carboxylase in both treatment groups (P < 0.01). The activity of citrate synthase was increased
in liver and adipose tissue of rats fed, CLA and VA+CLA diets (p < 0.001) compared to obese control, suggesting
increased mitochondrial fatty acid oxidative capacity.
Conclusion: We demonstrate that the hypolipidemic effects of chronic cis-9, trans-11 CLA supplementation on
circulating dyslipidemia and hepatic steatosis are enhanced by the addition of VA in the JCR:LA-cp rat.
Introduction
Conjugated linoleic acid (CLA) is a term that refers to
diverse positional and geometrical isomers of linoleic
acid and its numerous health related effects have been
extensively investigated. CLA was first described as a
potent anti-carcinogenic component and more recently
has been associated with improving dyslipidemia, insulin
sensitivity and the pro-inflammatory state related to
obesity and the metabolic syndrome [1,2]. However,
some animal studies (specifically those using mouse
models), in addition to a handful of clinical trials, have
indicated that the major isomers found in CLA mixtures
(cis-9, trans-11 CLA and trans-10, cis-12 CLA) are
responsible for different physiological effects [1-10].* Correspondence: spencer.proctor@ualberta.ca
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CLA is found naturally in ruminant-derived lipids and
cis-9, trans-11 CLA is the major natural isoform,
accounting for about 80-90% of the total CLA isomers
[11]. Trans-11 vaccenic acid (VA) is the precursor to
endogenous synthesis of the cis-9, trans-11 CLA isomer
in rats [12,13] and humans [14], and is the predominant
isomer of the total trans fatty acids found in ruminant-
derived fats such as dairy and meat products. We have
shown previously that unlike industrially produced trans
fatty acids, VA has lipid-lowering properties associated
with reduced hepatic lipogenesis and chylomicron secre-
tion in the obese and insulin resistant JCR:LA-cp rat
[15]. Interestingly, our observations indicate that VA has
neutral effects under normolipidemic conditions and
induces hypotriglyceridemic effects under conditions of
dyslipidemia [16]. We also observed that VA supple-
mentation for 16 weeks had a greater potential to influ-
ence lipoprotein metabolism [15] compared to a shorter
term feeding [16]. These findings are supported by sev-
eral clinical [17-19] and animal studies [20-24] showing
that dietary trans fats derived from ruminants have
either neutral or beneficial effects on cardiovascular dis-
ease risk factors compared to industrially produced
trans fats.
As a result of the increasing evidence associating CLA
and more recently VA with health benefits, there has
been a growing interest to increase the concentrations
of these natural trans fats in meat and dairy products
[25-28]. Interestingly, both VA and CLA (cis-9, trans-
11) can account for more than 15% of the total fat in
naturally enhanced dairy products [26] which could pro-
vide an additional health value to animal-derived fats.
Consequently, in this study we hypothesized that
chronic supplementation with both CLA and VA would
enhance the lipid lowering effects to improve whole
body lipid metabolism. Therefore, the aim of this study
was to evaluate the effect of dietary supplementation
with purified forms of both cis-9, trans-11 CLA and VA
on impaired lipid metabolism in an established animal
model of the metabolic syndrome, the JCR:LA-cp rat.
Materials and methods
Animals and diets
All experimental procedures were approved by the
University of Alberta Animal Ethics Committee and
conducted in accordance with the Canadian Council
on Animal Care. Twenty four male obese JCR:LA-cp
rats (cp/cp) were raised in our established breeding
colony at the University of Alberta as previously
described [29]. At 3 wk of age, rats were transferred
from the isolated breeding colony areas to an individu-
ally ventilated caging environment (TecniplastTM,
Exton PA, USA) and had access to a standard rat
chow diet (5001, PMI Nutrition International) (see
Additional file 1). At 8 wk of age, rats (n = 8) were
randomized and assigned to one of three diets for 16
wk (control and experimental diets) and had free
access to food and water. Age and weight matched
lean littermates (n = 8) were fed the control diet to
mimic cholesterol/high fat feeding under normolipi-
demic conditions. Food intake and body weight (BW)
were monitored weekly throughout the study. At 23
wk of age, a meal tolerance test (MTT) as previously
described [30], was performed in four randomly chosen
rats from control and treatment groups in order to
determine plasma glucose and insulin concentrations
after a meal. We also performed an oral fat challenge
test (OFC), as previously described [29] in four addi-
tional rats from each group. At the end of the treat-
ment period (24 wk of age), rats were fasted overnight
and anesthetized using isofluorane anesthesia. Plasma
was sampled from the left ventricle and heart, liver
and fat pads were excised, weighted and immediately
frozen at -80°C until analysis. Adipose fatty acid com-
position was measured from total triglyceride on the
epidydimal fat pad as previously described [16].
Three iso-caloric diets were prepared with a constant
polyunsaturated to saturated fatty acid ratio (P:S) of 0.4.
A control diet (CD) was supplemented (w/w) with 1%
cholesterol and contained 42% of energy from carbohy-
drate, 23.7% from protein and 34.3% from fat. Experi-
mental diets were prepared by adjusting the lipid
composition of the CD to provide 1.0% w/w of cis-9,
trans-11 CLA alone (CLA), both 1% of VA and 1% w/w
of cis-9, trans-11 CLA (VA+CLA). Semi-purified cis-9,
trans-11 CLA (G-c9t11 80:20) containing 59.8% of cis-9,
trans-11 CLA and 14.4% of trans-10, cis-12 CLA was
kindly provided by Lipid Nutrition. The amount of CLA
and VA (1% w/w) was chosen based on previous studies
allowing for metabolic sufficiency while maintaining a
normal dietary fatty acid proportion [15-17,31]. Purified
VA was synthesized by a chemical alkali isomerisation
from linoleic acid-rich vegetable oil [32]. The diet mix-
ture was extruded into pellets, dried at RT°C and stored
at 4°C. Fatty acid composition of the three diets was
confirmed by gas chromatograph analysis [28] of the fat
blend samples (Table 1).
Plasma biochemical components
The concentration of biochemical parameters in fasting
plasma from lean and obese groups were assessed using
commercially available homogenous, enzymatic colori-
metric assays. Triglyceride (TG) (Wako Pure Chemical
Industries, catalog no. 998-40391, 0.01 mmol/L mini-
mum), Total cholesterol (TC) (Wako Pure Chemical
Industries, catalog no. 993-00404, 0.002 mmol/L mini-
mum), LDL cholesterol (LDL-C) (Wako Pure Chemical
Industries, catalog no. 993-00404, 0.03-10.4 mmol/L)
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and nonesterified fatty acids (NEFA) (HR Series NEFA-
HR, catalog no. 999-34691, Wako Diagnostics) were
measured using direct colorimetric chemical enzymatic
reactions. Plasma glucose was measured as per the glu-
cose oxidase method (Diagnostic Chemical, catalog no.
220-32, 0.03-33.3 mmol/L) and plasma insulin was
determined using commercially available enzymatic
immunoassays for rodents (Ultrasensitive rat insulin
ELISA, Mercodia, catalog no. 80-INSRTU-E01, 0.03-1.0
pmol/L). Samples were analyzed in triplicate using assay
kits from a single lot and performed in one single batch.
Tissue homogenization and hepatic TG
Liver and adipose tissue samples (0.5 g) were homoge-
nized in 200 μL lysis buffer [PBS (pH 7.4) with 1.5%
TritonX-100 and 1% protease inhibitor cocktail (Sigma)]
and and hepatic TG levels were determined by a com-
mercially available enzymatic colorimetric assay (Wako
Pure Chemical Industries, catalog no. 998-40391, 0.01
mmol/L minimum), using an aliquot of the whole
homogenate and adjusting by the protein concentration
of the homogenate [15]. The remainder of the homoge-
nate was centrifuged at 700 g for 15 min and the super-
natant was collected and stored at -80C for western blot
and citrate synthase activity analysis.
Hepatic and adipose tissue citrate synthase activity
Citrate synthase activity in liver and adipose tissue sam-
ples was determined using a commercially available kit
from Sigma (catalog no. CS0720). The coefficient of var-
iation of this assay in our laboratory is < 10%. The
citrate synthase activity was expressed as μmol/min/g
protein.
Relative protein abundance of lipogenic enzymes
Hepatic acetyl-CoA carboxylase-1 (ACC-1) and fatty
acid synthase (FAS) were determined by western blot
analysis as described elsewhere [33] with few modifica-
tions [15]. ACC-1 and FAS relative abundance were
normalized based on the respective b-actin protein mass
(internal control).
Statistical analysis
Statistical analysis was performed using the Graph pad
Prism software, version 4.0. Data was tested for nor-
mal distribution and one-way ANOVA followed by
Tukey post-hoc tests were used to identify differences
among both lean and obese controls and treatment
groups (CLA and VA+CLA). Post-prandial glucose and
insulin metabolism as well as post-prandial TG
response were assessed by area under the curve (AUC)
analysis. Fasting concentrations of these parameters
were further subtracted from the total AUC to yield
the incremental area under the curve (iAUC). Results
are expressed as means ± SEM and the level of signifi-
cance was set at p < 0.05.
Results
Food intake, body weight and body composition
Obese rats fed the combination of VA+CLA showed
increased food intake compared to those obese rats fed
either the CD or CLA diet. Paradoxically, the VA+CLA
fed rats showed reduced body weight (p < 0.001) com-
pared to the CLA group (Table 2). Despite the higher
body weight of rats fed the CLA diet as compared to
obese control, no difference was observed in absolute
and relative heart weights or fat pad deposition (p >
0.05), as measured by the amount of absolute and rela-
tive perirenal and inguinal fat pad weights compared
with the obese rats fed the CD (Table 2). In contrast,
feeding either the CLA or the VA+CLA diet resulted in
a lower absolute liver weight by 15% and 26%, respec-
tively, and both diets reduced the ratio of liver weight to
total body weight by 22% as compared to obese rats fed
the CD (p < 0.001).
Citrate synthase activity in liver and adipose tissue
The activity of citrate synthase in liver and adipose tis-
sue is shown in Figure 1. There was a higher (p < 0.001)
citrate synthase activity in liver and inguinal adipose
Table 1 Fatty acid composition (% of total fatty acids) of
control and experimental diets
Fatty acid Control diet (CD) CLA diet VA+CLA diet
C16:0 9.1 8.5 9.1
C18:0 47.3 46.9 44.3
18:1 t-11 (VA) ND ND 5.6
18:1 c-9 (OA) 17.3 11.4 10.5
18:1 c-11 ND 0.5 0.5
C18:2 n6 (LA) 23.3 23.4 20.4
C18:3 n3 (ALA) 1.6 1.7 1.6
CLA c-9, t-11 0 5.2 3.9
CLA t-10, c-12 ND 1.1 0.8
other CLA ND 0.3 0.3
Summary
∑ total SFA2 57.2 56.3 54.2
∑ C12:0, C14:0, C16:03 9.1 8.5 9.1
∑ cis MUFA4 17.4 12.0 11.1
∑ PUFA5 25.0 25.1 22.0
∑ n-6 PUFA 23.4 23.4 22.0
∑ n-3 PUFA 1.6 1.7 1.6
P/S ratio6 0.4 0.4 0.4
∑ CLA 0.0 6.6 5.0
1. No detectable
2 Sum of all saturated fatty acids
3 Sum of lauric, myristic and palmitic acids
4 cis MUFA, sum of all monounsaturated excepting trans fatty acids
5 Sum of all polyunsaturated fatty acids excepting CLA
6 Ratio of polyunsaturated to saturated fatty acids
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tissue after feeding either CLA or VA+CLA diets as
compared to lean and obese rats fed the CD. Interest-
ingly, the citrate synthase activity in liver and adipose
tissue did not differ between lean and obese rats fed the
CD (p > 0.05).
Fatty acid profile in epididymal adipose tissue triglyceride
The fatty acid composition in adipose tissue triglyceride
was shown to directly reflect the dietary fatty acid com-
position as shown in Table 3. Obese rats fed with the
CLA and VA+CLA diets had a markedly increased pro-
portion of the cis-9, trans-11 CLA isomer relative to the
obese control group. The content of this isomer,
expressed as a percentage of total fatty acids was differ-
ent between the treated groups. The CLA diet showed
the greatest incorporation of the cis-9, trans-11 CLA
isomer (70 fold greater than control group) compared to
the VA+CLA diet, which was only 46 fold higher than
the obese control group. Rats fed VA+CLA diet showed
a greater incorporation of trans-11 18:1 (VA) compared
to CLA and obese control rats (p < 0.001). Interestingly,
rats fed the VA+CLA diet had lower proportions of
linoleic acid (18:2 n6), a-linolenic acid (18:3 n3) and
arachidonic acid (20:4 n6).
Fasting plasma lipid, glucose and insulin concentrations
As shown in Table 4, fasting plasma TG, TC and LDL-C
were significantly lower in obese rats fed either the CLA
or the VA+CLA diet, as compared to the CD. However,
feeding the VA+CLA diet further reduced plasma NEFA
concentration relative to the CLA fed rats and lowered
TG and LDL-C concentrations not different from lean
rats fed the CD (p > 0.05). The CLA or VA+CLA diet
lowered fasting insulin to that comparable of lean rats
(p > 0.05) and reduced total insulin concentration
(AUC) after the MTT (p < 0.05). There was no
Table 2 Food intake, body weight and body composition of rats in dietary groups
Dietary groups
Lean control Obese control Obese CLA Obese VA+CLA
Food intake (g/day) 19.7 ± 0.3c 32.4 ± 0.5b 31.4 ± 0.6b 36.1 ± 0.6***a
BW/16 wk (g) 384 ± 8.2c 646 ± 9.3b 702 ± 17.9a* 624 ± 9.5b
Heart (g) 0.89 ± 0.0b 1.19 ± 0.0a 1.26 ± 0.0a 1.23 ± 0.0a
weight, %BW 0.23 ± 0.0a 0.18 ± 0.0b 0.18 ± 0.0b 0.20 ± 0.0b
Liver (g) 9.1 ± 0.4d 23.1 ± 0.7a 19.7 ± 0.6***b 17.2 ± 0.3***c
weight, %BW 2.4 ± 0.1c 3.6 ± 0.1a 2.8 ± 0.1***b 2.8 ± 0.0***b
Perirenal FP1 (g) 1.3 ± 0.1c 7.4 ± 0.4ab 8.6 ± 0.8a 6.7 ± 0.4b
weight, %BW 0.33 ± 0.0b 1.2 ± 0.1a 1.2 ± 0.1a 1.1 ± 0.1a
Inguinal FP (g) 1.4 ± 0.2b 17.9 ± 1.1a 18.5 ± 1.0a 15.7 ± 1.0a
weight, %BW 0.36 ± 0.0b 2.8 ± 0.2a 2.6 ± 0.1a 2.5 ± 0.1a
Values are means ± SEM, n = 8. Means in the same raw with different symbol are significantly different as compared to obese control; *P < 0.05, **P < 0.01, ***P
< 0.001. Means in the same raw with different letter are significantly different among control (lean and obese) and obese treated groups (CLA and VA+CLA).
FP1= Fat pad
Figure 1 Citrate synthase activity in liver, perirenal and inguinal adipose tissue. Values are mean ± SEM, n = 8. Means with different
symbol are significantly different as compared to obese control; *P < 0.05, **P < 0.01, ***P < 0.001. Means with different letter are significantly
different among control (lean and obese) and obese treated groups (CLA and VA+CLA). AT, adipose tissue.
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statistical difference between groups for either glucose
metabolism (fasting or iAUC) or the relative change
(iAUC) in insulin.
Post-prandial plasma TG response
Obese rats had a higher post-prandial plasma TG
response (iAUC) compared to lean rats following an
OFC (Figure 2). AUC analysis showed an improved total
TG concentration (p < 0.05) over the 10-h post-prandial
period in rats fed either the CLA or VA+CLA diet (35 ±
5 and 38 ± 8 mmol/L.h, respectively), compared to
obese rats fed the CD (62 ± 5 mmol/L.h). However, the
post-prandial iAUC for TG was not different between
obese control and obese treatment groups (CLA and VA
+CLA).
Liver TG concentration and relative abundance of hepatic
lipogenic enzymes
Liver TG concentration was higher in obese control rats
compared to lean control rats. However, feeding the
CLA diet resulted in a liver triglyceride concentration
that was 22% lower than the obese rats fed the CD
(Table 4). Interestingly, the VA+CLA diet further low-
ered liver TG concentration by 43% and 27% as com-
pared to obese control and CLA groups, respectively. In
addition, CLA and VA+CLA diets resulted in signifi-
cantly lower hepatic ACC-1 protein abundance relative
to obese control (34% and 38%, respectively) and was
normalized to concentrations similar to lean rats fed the
CD (p > 0.05) (Figure 3A, B). The relative abundance of
hepatic FAS protein did not differ between the obese
groups (p > 0.05) (Figure 3A, C).
Discussion
Combination of VA+CLA increases food intake and
decreases liver weight
Dyslipidemia and insulin resistance are common fea-
tures associated with cardiovascular disease and the
metabolic syndrome. The homozygous obese (cp/cp),
JCR:LA-cp rat, has a complete absence of the leptin
receptor. As a consequence, the JCR:LA-cp rat sponta-
neously develops hyperphagia and obesity, associated
dyslipidemia, insulin resistance, and macro-and micro-
vascular dysfunction [34-36]. In the present study, we
Table 3 Fatty acid composition (% of total fatty acids) of triglyceride in epididymal adipose tissue
Dietary groups
Lean control Obese control Obese CLA Obese VA+CLA
Fatty acid
C18:0 13.91 ± 0.71a 6.36 ± 0.14b 5.47 ± 0.07b 6.31 ± 0.17b
C18:1 t-11 (VA) 0.05 ± 0.01b 0.02 ± 0.00b 0.08 ± 0.00b 1.72 ± 0.06***a
C18:1 c-9 28.37 ± 0.14d 37.9 ± 0.56a 32.72 ± 0.32***c 35.21 ± 0.49**b
C18:2 n6 35.76 ± 0.22a 20.51 ± 0.24b 20.15 ± 0.25b 15.06 ± 0.52***c
C18:3 n3 1.2 ± 0.03a 0.91 ± 0.02b 0.96 ± 0.02b 0.47 ± 0.06***c
CLA c-9, t-11 0.05 ± 0.01c 0.04 ± 0.01c 2.85 ± 0.04***a 1.91 ± 0.09***b
C20:4 n6 0.45 ± 0.01a 0.33 ± 0.25b 0.32 ± 0.01b 0.22 ± 0.0**c
Values are mean ± SEM, n = 8. Means in the same raw with different symbol are significantly different as compared to obese control; *P < 0.05, **P < 0.01,
***P < 0.001. Means in the same raw with different letter are significantly different among control (lean and obese) and obese treated groups (CLA and VA+CLA).
Long chain n3 PUFA were not detectable.
Table 4 Fasting plasma lipid concentrations, glucose and insulin AUC after MTT and hepatic TG
Dietary groups
Lean control Obese control Obese CLA Obese VA+CLA
TG (mmol/L) 0.47 ± 0.0c 3.28 ± 0.4a 2.05 ± 0.3*b 1.4 ± 0.1***bc
NEFA (mmol/L) 0.20 ± 0.02c 0.48 ± 0.02ab 0.57 ± 0.03a 0.42 ± 0.05b
TC (mmol/L) 2.26 ± 0.0c 6.18 ± 0.4a 4.22 ± 0.2***b 4.92 ± 0.2**b
LDL-C (mmol/L) 0.97 ± 0.1c 2.28 ± 0.2a 1.56 ± 0.1**b 1.2 ± 0.1***bc
Fasting glucose (mmol/L) 5.94 ± 0.08 6.81 ± 0.4 5.94 ± 0.36 6.75 ± 0.72
Glucose iAUC (mmol/L.h) 45.19 ± 4.5 52.22 ± 7.8 70.25 ± 14.7 42.7 ± 33.05
Fasting insulin (μIU/L) 73.41 ± 27.4b 629.2 ± 165.3a 216 ± 13.6*b 372.8 ± 98.24ab
Insulin AUC (μIU/L.h) 8739 ± 1566 c 40437 ± 4384 a 24548 ± 3465*b 23001 ± 2744*b
Insulin iAUC (μIU/L.h) 4452 ± 1464 11805 ± 7603 11585 ± 3885 4451 ± 3015
Liver TG (mmol/g protein) 2.2 ± 0.3d 21.2 ± 1.0a 16.6 ± 1.1*b 12.1 ± 1.3***c
Plasma lipid and liver TG values are mean ± SEM, n = 8. Insulin AUC is mean ± SEM, n = 4. Means in the same raw with different symbol are significantly
different as compared to obese control; *P < 0.05, **P < 0.01, ***P < 0.001. Means in the same raw with different letter are significantly different among control
(lean and obese) and obese treated groups (CLA and VA+CLA).
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used this unique animal model to evaluate hypolipi-
demic effects of cis-9, trans-11 CLA in combination
with VA. Obese rats fed the CLA diet had a higher final
body weight relative to obese control rats. However, this
was not associated with an increase in fat deposition.
Cis-9, trans-11 CLA has been observed to regulate
metabolic pathways involved in fatty acid oxidation as
well as energy production and thermogenesis [37-40];
therefore we investigated whether combination VA
+CLA might promote fatty acid oxidation.
CLA and VA+CLA promote mitochondrial fatty acid
oxidation in liver and adipose tissue
Peroxisome proliferator-activated receptor (PPAR)-ago-
nists, such as thiazolidenediones (TZDs), are effective
drugs for the treatment of type 2 diabetes by inducing
adipogenesis as well as increasing the uptake and meta-
bolism of free fatty acids in adipose tissue. Increased
mitochondrial oxidative capacity of white adipose tissue
has been observed after treatment with TZD [41,42].
CLA is a natural PPAR ligand [43-45] and has been
observed to promote fatty acid oxidation [40] or TG
synthesis in adipose tissue contributing to lower circu-
lating NEFA and TG concentrations [7]. We observed a
significant increase in citrate synthase activity in liver
and inguinal adipose tissue following supplementation
with either CLA or VA+CLA diet but not in perirenal
adipose tissue. Interestingly, citrate synthase activity was
not different between lean and obese control rats. It has
been reported that insulin resistance is associated with
an increase in muscle mitochondrial content and oxida-
tive capacity [46-48]. Similarly, it has been demonstrated
that mitochondrial biogenesis increases during adipose
tissue differentiation [49]. Therefore, it can be proposed
that JCR:LA-cp rats maintain similar mitochondrial fatty
acid oxidation relative to lean rats but during increased
dietary lipid consumption, it is insufficient to prevent
TG deposition. Treatment with CLA or VA+CLA may
stimulate mitochondrial fatty acid oxidation and in turn
this may contribute to improvements in liver and adi-
pose tissue metabolism in the JCR:LA-cp rat.
Incorporation of CLA and VA in adipose tissue
triglyceride
It is well established that the fatty acid composition of
adipose tissue is dependent on dietary intake. However,
endogenous synthesis of fatty acids, fatty acid transport
and inter-conversion processes (elongation and desa-
turation) are also significant contributing factors to the
composition of adipose tissue [50]. As expected, supple-
mentation with cis-9, trans-11 CLA (CLA diet) and VA
(VA+CLA diet) increased the proportion of these fatty
acids in adipose tissue from obese rats. We also wish to
note that the endogenous synthesis of cis-9, trans-11
CLA from VA may have also occurred in this study. In
both humans and animals, the conversion of dietary VA
to CLA has been reported to be at a rate of approxi-
mately 12-19% [12 and 14]. We also note that the diet-
ary ratio of VA:CLA in this study was ~1.5:1,
respectively (Table 1) and that the resultant incorpora-
tion of these fatty acids into adipose tissue was found to
be 1:1 following supplementation (Table 3). While we
cannot infer a rate of conversion from VA to CLA per
se from this data, it would support that previously
published.
Combined dietary VA+CLA has a greater effect to reduce
dyslipidemia and hepatic steatosis
One of the most striking effects of the combined treat-
ment (VA+CLA) in the present study was the reduction
Figure 2 Post-prandial triglyceride response following an oral fat challenge. Values are mean ± SEM, n = 4. AUC differ relative to obese
rats fed the CD; bP < 0.05, cP < 0.001. iAUC differ relative to obese rats fed the CD; ***P < 0.001.
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Figure 3 Effects of CLA and VA+CLA on hepatic protein abundance of lipogenic enzymes. Western blots of hepatic lipogenic enzymes (A),
and relative abundance of ACC-1 (B) and FAS (C). Values are mean ± SEM, n = 8. Means with different symbol are significantly different as
compared to obese rats fed the CD; *P < 0.05, **P < 0.01, ***P < 0.001. Means with different letter are significantly different among control (lean
and obese) and obese treated groups (CLA and VA+CLA).
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in hepatic TG concentration. The improvement in fast-
ing lipid parameters by VA+CLA diet (i.e. TG and LDL-
C) suggest an additional benefit with the combination
diet and is consistent with previous observations that
dietary VA has lipid lowering properties independent
from CLA [15]. We also wish to note that both diets
(CLA and VA+CLA) consistently contained 0.15 w/w of
the trans-10, cis-12 CLA isomer, which is also known
for its hypolipidemic properties.
ACC-1 and FAS are two key lipogenic enzymes
involved in the synthesis of fatty acids and subsequent
TG synthesis. TG is then either stored as lipid droplets
within the hepatocyte, secreted into the blood compart-
ment as VLDL or hydrolyzed via oxidation [51]. It is
plausible that reduced hepatic lipogenesis may contribute
(at least in part) to reduced hepatic TG in rats fed either
the CLA or VA+CLA diet, which is supported by a lower
hepatic ACC-1 protein abundance relative to obese rats
fed the CD. We have reported previously that VA may
act in part via ACC-1 and FAS pathways resulting in
reduced VLDL secretion to decrease circulating concen-
trations of plasma TG and LDL-C [15]. However, in con-
ditions of insulin resistance, hepatic steatosis is thought
to be caused by an increased free fatty acid flux from adi-
pose tissue into the liver [52]. As discussed above, rats
fed the combined treatment (VA+CLA) showed lower
circulating NEFA concentrations compared to rats fed
the CLA diet alone. We propose that reduced NEFA may
also contribute to a further decrease in hepatic TG. In
addition, activation of ACC is regulated by phosphoryla-
tion/dephosphorylation [53] and thus, it may be possible
that CLA and VA+CLA diets may differently regulate
post-translational modifications of ACC-1.
Conclusion
In conclusion, results in this study confirm hypolipi-
demic effects of chronic supplementation with cis-9,
trans-11 CLA alone or in combination with trans-11
VA in the dyslipidemic and insulin resistant JCR:LA-cp
rat. Our data also support the hypothesis that a dietary
formulation enriched with both CLA and VA may
further enhance their hypolipidemic properties, particu-
larly during conditions of hypertriglyceridemia, hyperch-
olesterolemia and/or hepatic steatosis.
Additional material
Additional file 1: Changes in body weight throughout the study
and schematic representation of the experimental design. Rats (n =
8) were fed a standard chow diet prior to the study (from 3-8 wk of
age). Then, control and experimental diets were provided for 16 wk. An
oral fat challenge test (OFC) and a meal tolerance test (MTT) were
conducted on different rats (n = 4 in each test).
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